Magazine Article | May 2, 2022

Companies To Watch: Castle Creek Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Many stakes are at play in targeting rare skin, connective tissue, liver, and metabolic disorders.

SNAPSHOT
Castle Creek Biosciences is in late-stage development of gene therapies for rare connective tissue conditions. Its most advanced products, ex vivo therapies based on the company’s proprietary autologous fibroblast technology platform, are localized treatments administered at disease sites. New early-stage products from a recent acquisition have added in vivo, or inside the body, gene therapies, which act against the root causes of targeted diseases. The lead product, D-Fi (coded FCX-007), is now entering late-stage trials for localized treatment of skin blisters and wounds due to dystrophic epidermolysis bullosa (DEB), a rare but horrific inherited condition. Next in line is FCX-013, now in Phase 1/2, treating localized scleroderma. Other ex vivo therapies, including some to treat rare collagen disorders, are in discovery stages tightly focused on rare connective tissue conditions. In vivo gene therapies are in preclinical studies for rare metabolic and liver diseases.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: